| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydrocortisone | 63 | 2026 | 192 | 11.460 |
Why?
|
| Hair | 42 | 2023 | 81 | 6.390 |
Why?
|
| Stress, Psychological | 30 | 2026 | 474 | 5.310 |
Why?
|
| Macaca mulatta | 38 | 2025 | 260 | 4.420 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 17 | 2013 | 19 | 4.010 |
Why?
|
| Hypothalamo-Hypophyseal System | 20 | 2024 | 86 | 3.490 |
Why?
|
| Stress, Physiological | 17 | 2025 | 210 | 2.840 |
Why?
|
| Pituitary-Adrenal System | 19 | 2024 | 59 | 2.740 |
Why?
|
| Behavior, Animal | 19 | 2019 | 234 | 2.560 |
Why?
|
| Prenatal Exposure Delayed Effects | 10 | 2025 | 155 | 2.010 |
Why?
|
| Self-Injurious Behavior | 9 | 2021 | 48 | 1.960 |
Why?
|
| Alopecia | 6 | 2019 | 28 | 1.890 |
Why?
|
| Saliva | 11 | 2022 | 100 | 1.760 |
Why?
|
| Nails | 5 | 2025 | 39 | 1.760 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 9 | 2013 | 23 | 1.500 |
Why?
|
| Mother-Child Relations | 6 | 2025 | 45 | 1.470 |
Why?
|
| Mothers | 15 | 2025 | 280 | 1.440 |
Why?
|
| Neurotoxicity Syndromes | 5 | 2011 | 23 | 1.420 |
Why?
|
| Anxiety | 10 | 2026 | 426 | 1.260 |
Why?
|
| Animals | 75 | 2025 | 21345 | 1.210 |
Why?
|
| Serotonin Agents | 6 | 2013 | 10 | 1.200 |
Why?
|
| Brain | 16 | 2025 | 1605 | 1.200 |
Why?
|
| Male | 85 | 2026 | 31047 | 1.130 |
Why?
|
| Rats | 21 | 2016 | 1994 | 1.100 |
Why?
|
| Hallucinogens | 6 | 2009 | 13 | 1.030 |
Why?
|
| Female | 76 | 2026 | 34018 | 1.010 |
Why?
|
| Fluorocarbons | 2 | 2024 | 52 | 1.000 |
Why?
|
| Serotonin | 9 | 2012 | 62 | 1.000 |
Why?
|
| Rats, Sprague-Dawley | 17 | 2013 | 624 | 0.990 |
Why?
|
| Refugees | 5 | 2026 | 75 | 0.950 |
Why?
|
| Maternal Behavior | 4 | 2020 | 31 | 0.910 |
Why?
|
| Animals, Newborn | 12 | 2025 | 241 | 0.890 |
Why?
|
| Pregnancy | 22 | 2025 | 2372 | 0.890 |
Why?
|
| Biomarkers | 9 | 2026 | 1480 | 0.850 |
Why?
|
| Cocaine | 6 | 2019 | 101 | 0.810 |
Why?
|
| Primates | 6 | 2020 | 52 | 0.770 |
Why?
|
| Body Temperature | 6 | 2013 | 44 | 0.760 |
Why?
|
| Motor Activity | 7 | 2013 | 345 | 0.730 |
Why?
|
| Disease Models, Animal | 8 | 2024 | 2293 | 0.710 |
Why?
|
| Social Class | 5 | 2025 | 137 | 0.680 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2022 | 404 | 0.670 |
Why?
|
| Fever | 2 | 2011 | 65 | 0.650 |
Why?
|
| Infant | 16 | 2025 | 1693 | 0.650 |
Why?
|
| Humans | 57 | 2026 | 65140 | 0.640 |
Why?
|
| Callithrix | 3 | 2018 | 21 | 0.630 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 129 | 0.630 |
Why?
|
| Child Development | 7 | 2025 | 87 | 0.630 |
Why?
|
| Child, Preschool | 11 | 2022 | 2061 | 0.620 |
Why?
|
| Child | 16 | 2024 | 4607 | 0.580 |
Why?
|
| Cebus | 1 | 2018 | 1 | 0.560 |
Why?
|
| Lactation | 2 | 2015 | 78 | 0.550 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 14 | 0.550 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 180 | 0.530 |
Why?
|
| Adaptation, Psychological | 4 | 2026 | 279 | 0.530 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2019 | 856 | 0.500 |
Why?
|
| Students | 1 | 2019 | 224 | 0.500 |
Why?
|
| Social Behavior | 8 | 2019 | 85 | 0.500 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 77 | 0.500 |
Why?
|
| Cerebral Cortex | 3 | 2013 | 269 | 0.490 |
Why?
|
| Sleep | 3 | 2021 | 240 | 0.490 |
Why?
|
| Dronabinol | 2 | 2011 | 31 | 0.490 |
Why?
|
| Aggression | 6 | 2019 | 79 | 0.480 |
Why?
|
| Emotions | 3 | 2019 | 233 | 0.480 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 10 | 0.470 |
Why?
|
| Brain Waves | 2 | 2025 | 8 | 0.460 |
Why?
|
| Monkey Diseases | 3 | 2019 | 7 | 0.450 |
Why?
|
| Body Weight | 8 | 2013 | 376 | 0.440 |
Why?
|
| Adult | 21 | 2026 | 17358 | 0.440 |
Why?
|
| Mental Health | 4 | 2026 | 361 | 0.430 |
Why?
|
| Endocrine System Diseases | 1 | 2014 | 11 | 0.410 |
Why?
|
| Attention | 5 | 2019 | 151 | 0.410 |
Why?
|
| Depression | 7 | 2026 | 900 | 0.410 |
Why?
|
| Neuropsychiatry | 1 | 2014 | 9 | 0.410 |
Why?
|
| Dopamine | 2 | 2012 | 108 | 0.400 |
Why?
|
| Emigrants and Immigrants | 2 | 2026 | 47 | 0.400 |
Why?
|
| Protein Binding | 5 | 2012 | 1640 | 0.390 |
Why?
|
| Brain Chemistry | 3 | 2009 | 76 | 0.390 |
Why?
|
| Mood Disorders | 1 | 2014 | 79 | 0.390 |
Why?
|
| Environmental Pollutants | 2 | 2024 | 97 | 0.380 |
Why?
|
| Age Factors | 8 | 2019 | 1586 | 0.380 |
Why?
|
| Adolescent | 13 | 2026 | 6297 | 0.370 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2012 | 34 | 0.370 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 81 | 0.360 |
Why?
|
| Mindfulness | 2 | 2024 | 71 | 0.360 |
Why?
|
| Citalopram | 3 | 2011 | 22 | 0.360 |
Why?
|
| Analysis of Variance | 8 | 2016 | 602 | 0.360 |
Why?
|
| Phenotype | 1 | 2016 | 1233 | 0.350 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 407 | 0.350 |
Why?
|
| Fear | 4 | 2022 | 71 | 0.340 |
Why?
|
| Mental Disorders | 2 | 2022 | 822 | 0.340 |
Why?
|
| Pilot Projects | 6 | 2026 | 1015 | 0.340 |
Why?
|
| Poverty | 3 | 2023 | 304 | 0.340 |
Why?
|
| Hydroxyindoleacetic Acid | 5 | 2012 | 11 | 0.330 |
Why?
|
| Young Adult | 12 | 2026 | 4809 | 0.330 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2009 | 2 | 0.310 |
Why?
|
| Carbolines | 1 | 2009 | 8 | 0.310 |
Why?
|
| Social Environment | 4 | 2016 | 93 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 2244 | 0.310 |
Why?
|
| Progesterone | 2 | 2015 | 165 | 0.310 |
Why?
|
| Electroencephalography | 3 | 2025 | 156 | 0.310 |
Why?
|
| Aging | 5 | 2025 | 771 | 0.300 |
Why?
|
| Cheirogaleidae | 1 | 2009 | 6 | 0.300 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2009 | 34 | 0.290 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2008 | 2 | 0.290 |
Why?
|
| Amphetamines | 1 | 2008 | 5 | 0.290 |
Why?
|
| Models, Animal | 2 | 2014 | 241 | 0.290 |
Why?
|
| Body Temperature Regulation | 2 | 2005 | 21 | 0.290 |
Why?
|
| Neurosecretory Systems | 1 | 2008 | 24 | 0.290 |
Why?
|
| Reproduction | 1 | 2009 | 98 | 0.280 |
Why?
|
| Sex Factors | 7 | 2024 | 992 | 0.280 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2024 | 12 | 0.280 |
Why?
|
| Socioeconomic Factors | 5 | 2025 | 801 | 0.280 |
Why?
|
| Cushing Syndrome | 2 | 2018 | 10 | 0.270 |
Why?
|
| Estradiol | 1 | 2009 | 259 | 0.270 |
Why?
|
| Peer Group | 3 | 2026 | 113 | 0.270 |
Why?
|
| Memory Disorders | 2 | 2005 | 52 | 0.270 |
Why?
|
| Testosterone | 4 | 2019 | 128 | 0.270 |
Why?
|
| Parents | 4 | 2024 | 410 | 0.270 |
Why?
|
| Neurotoxins | 2 | 2010 | 21 | 0.260 |
Why?
|
| Time Factors | 8 | 2012 | 3762 | 0.260 |
Why?
|
| Hippocampus | 3 | 2019 | 276 | 0.260 |
Why?
|
| Social Dominance | 3 | 2019 | 4 | 0.260 |
Why?
|
| Locomotion | 1 | 2008 | 111 | 0.260 |
Why?
|
| Social Support | 3 | 2026 | 391 | 0.250 |
Why?
|
| Membrane Transport Proteins | 2 | 2004 | 135 | 0.250 |
Why?
|
| Glucocorticoids | 3 | 2023 | 189 | 0.250 |
Why?
|
| DNA Methylation | 2 | 2025 | 302 | 0.240 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2006 | 5 | 0.240 |
Why?
|
| Neostriatum | 2 | 2009 | 26 | 0.240 |
Why?
|
| Infant, Newborn | 6 | 2024 | 1422 | 0.230 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2025 | 28 | 0.230 |
Why?
|
| Extinction, Psychological | 2 | 2004 | 14 | 0.230 |
Why?
|
| Middle Aged | 10 | 2026 | 18273 | 0.230 |
Why?
|
| Serotonin Syndrome | 1 | 2005 | 9 | 0.230 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 278 | 0.230 |
Why?
|
| Health Promotion | 3 | 2025 | 516 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 428 | 0.220 |
Why?
|
| Corticosterone | 3 | 2016 | 24 | 0.220 |
Why?
|
| Housing, Animal | 5 | 2016 | 15 | 0.220 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 662 | 0.210 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2024 | 4 | 0.210 |
Why?
|
| Hyperthermia, Induced | 1 | 2004 | 20 | 0.210 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2024 | 22 | 0.210 |
Why?
|
| Fenfluramine | 1 | 2003 | 5 | 0.200 |
Why?
|
| Amniotic Fluid | 1 | 2023 | 8 | 0.200 |
Why?
|
| Environment | 3 | 2016 | 125 | 0.200 |
Why?
|
| Serbia | 4 | 2026 | 5 | 0.200 |
Why?
|
| Phthalic Acids | 1 | 2024 | 41 | 0.200 |
Why?
|
| Sex Characteristics | 3 | 2020 | 213 | 0.200 |
Why?
|
| Income | 1 | 2024 | 169 | 0.190 |
Why?
|
| Reaction Time | 5 | 2019 | 130 | 0.190 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 232 | 0.190 |
Why?
|
| Reflex, Startle | 1 | 2002 | 7 | 0.190 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2019 | 26 | 0.190 |
Why?
|
| Farmers | 1 | 2022 | 20 | 0.180 |
Why?
|
| Animal Welfare | 2 | 2019 | 13 | 0.180 |
Why?
|
| Conditioning, Classical | 1 | 2002 | 7 | 0.180 |
Why?
|
| Maternal Deprivation | 3 | 2024 | 3 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2025 | 641 | 0.180 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 226 | 0.170 |
Why?
|
| Father-Child Relations | 1 | 2021 | 8 | 0.170 |
Why?
|
| Paternal Behavior | 1 | 2021 | 6 | 0.170 |
Why?
|
| Fathers | 1 | 2021 | 22 | 0.170 |
Why?
|
| Exploratory Behavior | 3 | 2011 | 36 | 0.170 |
Why?
|
| Receptors, Drug | 1 | 2000 | 4 | 0.170 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2000 | 8 | 0.160 |
Why?
|
| Receptors, Opioid, delta | 1 | 2000 | 5 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 105 | 0.160 |
Why?
|
| Receptors, Opioid, mu | 1 | 2000 | 13 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 108 | 0.160 |
Why?
|
| Amygdala | 1 | 2020 | 85 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 296 | 0.160 |
Why?
|
| Nucleus Accumbens | 1 | 2000 | 47 | 0.160 |
Why?
|
| Grooming | 2 | 2017 | 4 | 0.160 |
Why?
|
| White Matter | 1 | 2021 | 126 | 0.160 |
Why?
|
| Abattoirs | 1 | 2019 | 3 | 0.160 |
Why?
|
| Placenta | 1 | 2020 | 69 | 0.160 |
Why?
|
| Animal Husbandry | 1 | 2019 | 10 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2701 | 0.150 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 127 | 0.150 |
Why?
|
| Dopamine Agonists | 1 | 1999 | 22 | 0.150 |
Why?
|
| Reinforcement Schedule | 1 | 2019 | 8 | 0.150 |
Why?
|
| Attentional Bias | 1 | 2019 | 1 | 0.150 |
Why?
|
| Meat | 1 | 2019 | 38 | 0.150 |
Why?
|
| Benzazepines | 1 | 1999 | 21 | 0.150 |
Why?
|
| Sexual Maturation | 1 | 2019 | 52 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 353 | 0.150 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 59 | 0.140 |
Why?
|
| ROC Curve | 1 | 2019 | 292 | 0.140 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2019 | 43 | 0.140 |
Why?
|
| Diazepam | 2 | 2011 | 10 | 0.140 |
Why?
|
| Child Behavior | 1 | 2019 | 64 | 0.140 |
Why?
|
| Swine | 1 | 2019 | 394 | 0.140 |
Why?
|
| Anti-Anxiety Agents | 2 | 2011 | 31 | 0.140 |
Why?
|
| Parent-Child Relations | 1 | 2019 | 66 | 0.140 |
Why?
|
| Tetanus Toxoid | 1 | 2018 | 14 | 0.140 |
Why?
|
| Neurons | 1 | 2004 | 933 | 0.140 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2018 | 11 | 0.140 |
Why?
|
| Interpersonal Relations | 2 | 2011 | 160 | 0.140 |
Why?
|
| Binding, Competitive | 2 | 2010 | 96 | 0.140 |
Why?
|
| Universities | 1 | 2019 | 168 | 0.130 |
Why?
|
| Telomere | 1 | 2017 | 58 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 23 | 0.130 |
Why?
|
| Antibodies, Bacterial | 1 | 2018 | 181 | 0.130 |
Why?
|
| Impulsive Behavior | 1 | 2017 | 28 | 0.130 |
Why?
|
| Macaca nemestrina | 1 | 2016 | 9 | 0.120 |
Why?
|
| Milk | 1 | 2017 | 47 | 0.120 |
Why?
|
| Ejaculation | 2 | 2007 | 9 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 390 | 0.120 |
Why?
|
| Prolactin | 2 | 2008 | 40 | 0.120 |
Why?
|
| Maze Learning | 2 | 2007 | 51 | 0.120 |
Why?
|
| Death | 1 | 2016 | 33 | 0.120 |
Why?
|
| Family Characteristics | 1 | 2016 | 46 | 0.120 |
Why?
|
| Feasibility Studies | 3 | 2025 | 587 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 181 | 0.120 |
Why?
|
| Growth and Development | 1 | 2015 | 10 | 0.110 |
Why?
|
| Parenting | 1 | 2016 | 75 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 527 | 0.110 |
Why?
|
| Hormones | 1 | 2015 | 62 | 0.110 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2015 | 10 | 0.110 |
Why?
|
| Parity | 1 | 2015 | 71 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1698 | 0.110 |
Why?
|
| Bhutan | 2 | 2026 | 23 | 0.110 |
Why?
|
| Animal Communication | 1 | 2014 | 4 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2757 | 0.100 |
Why?
|
| Solid Phase Extraction | 1 | 2014 | 10 | 0.100 |
Why?
|
| Random Allocation | 4 | 2019 | 200 | 0.100 |
Why?
|
| Oxytocin | 1 | 2014 | 44 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2016 | 189 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2025 | 213 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 385 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 805 | 0.100 |
Why?
|
| Exercise | 1 | 2020 | 964 | 0.100 |
Why?
|
| Species Specificity | 1 | 2014 | 339 | 0.100 |
Why?
|
| Resilience, Psychological | 1 | 2014 | 66 | 0.090 |
Why?
|
| Child Abuse | 1 | 2014 | 89 | 0.090 |
Why?
|
| Electroshock | 2 | 2002 | 6 | 0.090 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 528 | 0.090 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2011 | 13 | 0.090 |
Why?
|
| Memory, Short-Term | 1 | 2011 | 63 | 0.080 |
Why?
|
| Hair Preparations | 1 | 2010 | 2 | 0.080 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 6 | 0.080 |
Why?
|
| Baths | 1 | 2010 | 7 | 0.080 |
Why?
|
| Memory | 2 | 2009 | 123 | 0.080 |
Why?
|
| Educational Status | 2 | 2024 | 277 | 0.080 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 2009 | 3 | 0.080 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2009 | 3 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2025 | 742 | 0.080 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2009 | 1 | 0.080 |
Why?
|
| Synaptosomes | 1 | 2009 | 16 | 0.080 |
Why?
|
| Methamphetamine | 1 | 2009 | 25 | 0.080 |
Why?
|
| Concept Formation | 1 | 2009 | 19 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 126 | 0.080 |
Why?
|
| Benzylamines | 1 | 2009 | 35 | 0.080 |
Why?
|
| Madagascar | 1 | 2009 | 4 | 0.080 |
Why?
|
| Drug Interactions | 3 | 2011 | 124 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 149 | 0.080 |
Why?
|
| Androgens | 1 | 2009 | 66 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 66 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2009 | 31 | 0.070 |
Why?
|
| Ketanserin | 1 | 2008 | 1 | 0.070 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2008 | 2 | 0.070 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2008 | 8 | 0.070 |
Why?
|
| Water | 1 | 2010 | 314 | 0.070 |
Why?
|
| Feces | 1 | 2009 | 118 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2021 | 2620 | 0.070 |
Why?
|
| Transcortin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 374 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1282 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2025 | 3308 | 0.060 |
Why?
|
| United States | 2 | 2025 | 8093 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 896 | 0.060 |
Why?
|
| Leuprolide | 3 | 2011 | 18 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 852 | 0.060 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2006 | 2 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2011 | 88 | 0.060 |
Why?
|
| Stereotypic Movement Disorder | 1 | 2005 | 1 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2005 | 33 | 0.060 |
Why?
|
| Rest | 1 | 2025 | 45 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2025 | 19 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 86 | 0.060 |
Why?
|
| Cognition | 1 | 2009 | 508 | 0.060 |
Why?
|
| Neurochemistry | 1 | 2005 | 2 | 0.060 |
Why?
|
| Macaca | 1 | 2005 | 30 | 0.060 |
Why?
|
| Photic Stimulation | 2 | 2019 | 89 | 0.060 |
Why?
|
| Pyridines | 1 | 2006 | 119 | 0.050 |
Why?
|
| Borderline Personality Disorder | 1 | 2005 | 14 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 247 | 0.050 |
Why?
|
| Prosencephalon | 1 | 2004 | 37 | 0.050 |
Why?
|
| Refugee Camps | 1 | 2024 | 2 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2005 | 83 | 0.050 |
Why?
|
| Catecholamines | 1 | 2004 | 31 | 0.050 |
Why?
|
| Amniocentesis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Kenya | 1 | 2024 | 97 | 0.050 |
Why?
|
| Models, Biological | 2 | 2008 | 1192 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2023 | 43 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 213 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1163 | 0.050 |
Why?
|
| Mice | 2 | 2014 | 11119 | 0.050 |
Why?
|
| Skin | 1 | 2006 | 422 | 0.050 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2002 | 5 | 0.050 |
Why?
|
| Homovanillic Acid | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genes, fos | 1 | 2002 | 18 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2024 | 164 | 0.050 |
Why?
|
| Acoustic Stimulation | 1 | 2002 | 62 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2016 | 497 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 226 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2002 | 199 | 0.040 |
Why?
|
| House Calls | 1 | 2021 | 23 | 0.040 |
Why?
|
| Congo | 1 | 2021 | 1 | 0.040 |
Why?
|
| Health Status | 1 | 2024 | 447 | 0.040 |
Why?
|
| Papio | 1 | 2020 | 21 | 0.040 |
Why?
|
| Phencyclidine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 755 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 77 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 250 | 0.040 |
Why?
|
| Sulfur Isotopes | 1 | 2000 | 3 | 0.040 |
Why?
|
| Actigraphy | 1 | 2021 | 51 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 199 | 0.040 |
Why?
|
| Nervous System | 1 | 2000 | 71 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2020 | 102 | 0.040 |
Why?
|
| Massachusetts | 1 | 2026 | 2145 | 0.040 |
Why?
|
| Weaning | 1 | 1999 | 7 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 42 | 0.040 |
Why?
|
| Videotape Recording | 1 | 1999 | 46 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 49 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2000 | 153 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2019 | 81 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 294 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 361 | 0.030 |
Why?
|
| Problem Behavior | 1 | 2017 | 12 | 0.030 |
Why?
|
| Family Relations | 1 | 2017 | 23 | 0.030 |
Why?
|
| Inflammation | 1 | 2024 | 1192 | 0.030 |
Why?
|
| Fixation, Ocular | 1 | 2017 | 33 | 0.030 |
Why?
|
| Play and Playthings | 1 | 2017 | 19 | 0.030 |
Why?
|
| Hydroxysteroids | 1 | 2017 | 1 | 0.030 |
Why?
|
| Territoriality | 1 | 2016 | 1 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1260 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1098 | 0.030 |
Why?
|
| Oregon | 1 | 2016 | 19 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 173 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 59 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 200 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 182 | 0.030 |
Why?
|
| Dermis | 1 | 2016 | 22 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2016 | 48 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 392 | 0.030 |
Why?
|
| Anesthesia | 1 | 2016 | 52 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 382 | 0.030 |
Why?
|
| Anemia, Neonatal | 1 | 2015 | 3 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 1630 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2026 | 5792 | 0.030 |
Why?
|
| Vaccination | 1 | 2018 | 377 | 0.030 |
Why?
|
| Life Change Events | 1 | 2015 | 66 | 0.030 |
Why?
|
| Imitative Behavior | 1 | 2014 | 7 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1559 | 0.030 |
Why?
|
| Oxytocics | 1 | 2014 | 13 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 166 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 159 | 0.030 |
Why?
|
| Facial Expression | 1 | 2011 | 16 | 0.020 |
Why?
|
| Fluoxetine | 1 | 2011 | 45 | 0.020 |
Why?
|
| Avoidance Learning | 1 | 2010 | 27 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 137 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2483 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 85 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2009 | 9 | 0.020 |
Why?
|
| Visual Perception | 1 | 2009 | 46 | 0.020 |
Why?
|
| Mental Recall | 1 | 2009 | 95 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 868 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 164 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 14965 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 198 | 0.020 |
Why?
|
| Orientation | 1 | 2008 | 25 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 673 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 739 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 410 | 0.020 |
Why?
|
| Movement | 1 | 2008 | 163 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1113 | 0.020 |
Why?
|
| Consciousness | 1 | 2006 | 12 | 0.020 |
Why?
|
| Laboratory Animal Science | 1 | 2005 | 1 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 2005 | 9 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 450 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 371 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 240 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1050 | 0.010 |
Why?
|
| Reward | 1 | 2004 | 89 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1419 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 6872 | 0.010 |
Why?
|